DeepMed Research

Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee

Phase 4

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Drug: Imotun
Drug: Placebo

First Posted Date: 2012-12-28

Last Posted Date: 2017-03-27

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 287

Registration Number: NCT01756937

Locations: 🇰🇷
Yeungnam university medical center, Daegu, Korea, Republic of
🇰🇷
hanyang University Guri Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Chung-Ang University hospital, Seoul, Korea, Republic of

and more 6 locations

Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Carvedilol SR 32mg, QD
Drug: Carvedilol IR 25mg, QD
Drug: Carvedilol SR 64mg, QD
Drug: Carvedilol IR 25mg, BID

First Posted Date: 2012-12-27

Last Posted Date: 2014-01-14

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 238

Registration Number: NCT01756430

Locations: 🇰🇷
The Hanyang Universitiy Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of

Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tacrolimus with Methotrexate

First Posted Date: 2012-12-11

Last Posted Date: 2015-08-11

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 111

Registration Number: NCT01746680

Locations: 🇰🇷
Kyung Hee University Hospital, Seoul, Korea, Republic of

The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee

Phase 4

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Drug: Imotun capsule
Drug: Imotun capsule placebo

First Posted Date: 2012-12-06

Last Posted Date: 2015-04-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 234

Registration Number: NCT01743287

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
🇰🇷
Bundang CHA medical center, Seongnam, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 7 locations

Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers

Phase 1

Completed

Conditions: Anemia

Interventions: Drug: NESP 60μg
Drug: CKD-11101 60μg

First Posted Date: 2012-09-14

Last Posted Date: 2017-05-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 34

Registration Number: NCT01685671

Locations: 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers

Phase 1

Completed

Conditions: Anemia

Interventions: Drug: NESP 60μg
Drug: CKD-11101 60μg

First Posted Date: 2012-09-13

Last Posted Date: 2017-05-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 31

Registration Number: NCT01684605

Locations: 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure

Phase 4

Completed

Conditions: Hypertension
Congestive Heart Failure

Interventions: Drug: Candemore tablet
Drug: Atacand tablet

First Posted Date: 2012-09-11

Last Posted Date: 2015-09-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 169

Registration Number: NCT01682564

Locations: 🇰🇷
Daegu catholic univ. medical center, Daegu, Nam-gu Daemyung-dong, Korea, Republic of
🇰🇷
Maryknoll medical center, Busan, Jung-gu Daecheong-dong, Korea, Republic of
🇰🇷
Gyeongsang national university hospital, Jinju, Chiram-dong, Korea, Republic of

and more 11 locations

Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Fixed dose combination of clopidogrel/Aspirin
Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2012-08-13

Last Posted Date: 2012-08-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 60

Registration Number: NCT01663038

Locations: 🇰🇷
Inje University Pusan Paik Hospital, Pusan, Korea, Republic of

Efficacy and Safety of CKD-828 to Stage 2 Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: CKD-828 2.5/40mg
Drug: S-amlodipine 2.5mg
Drug: CKD-828 5/40mg
Drug: S-amlodipine 5mg
Drug: CKD-828 5/80mg

First Posted Date: 2012-07-06

Last Posted Date: 2013-06-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 103

Registration Number: NCT01634295

Locations: 🇰🇷
Seoul national university Bundang Hospital, Bundang-gu, Gyeonggi-do, Korea, Republic of

Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

Phase 2

Completed

Conditions: Epithelial Ovarian Cancer

Interventions: Drug: Topotecan
Drug: Belotecan

First Posted Date: 2012-06-28

Last Posted Date: 2016-09-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 141

Registration Number: NCT01630018

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Seoul Metropolitan, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy